NASDAQ: ITCI - Intra-Cellular Therapies, Inc.

Yield per half year: +78.59%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Intra-Cellular Therapies, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc., биофармацевтическая компания, разрабатывает новые препараты для лечения психоневрологических и неврологических заболеваний и других заболеваний центральной нервной системы (ЦНС) в США. Компания разрабатывает свой ведущий кандидат на лекарство CAPLYTA для лечения шизофрении, биполярного расстройства, поведенческих нарушений, связанных с деменцией, аутизмом и другими заболеваниями ЦНС.

more details
Также разрабатывается ITI-002, который ингибирует фермент фосфодиэстеразу типа 1; ITI-214 для болезни Паркинсона; и ITI-333 для расстройств, связанных с употреблением психоактивных веществ, боли и сопутствующих психических заболеваний, включая депрессию и тревогу. Головной офис Intra-Cellular Therapies, Inc. находится в Нью-Йорке, штат Нью-Йорк.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2014-01-07
ISIN US46116X1019
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт https://www.intracellulartherapies.com
Цена ао 131.7
Change price per day: 0% (131.87)
Change price per week: 0% (131.87)
Change price per month: +0.4724% (131.25)
Change price per 3 month: +39% (94.87)
Change price per half year: +78.59% (73.84)
Change price per year: +100.17% (65.88)
Change price per 3 year: +155.36% (51.64)
Change price per 5 year: +403.32% (26.2)
Change price per year to date: +51.64% (86.96)
All parameters

Underestimation

Title Value Grade
P/S 12.65 1
P/BV 7.5 1
P/E 0 0
EV/EBITDA -71.28 0
Total: 1.63

Efficiency

Title Value Grade
ROA, % -7.13 0
ROE, % -8.58 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.1455 10
Total: 9.2

Growth impulse

Title Value Grade
Yield Revenue, % 2926.01 10
Yield Ebitda, % -49.52 0
Yield EPS, % -77.58 0
Total: 2
More

Institutions Volume Share, %
FMR, LLC 11457694 11.84
Vanguard Group Inc 9094302 9.39
Blackrock Inc. 8193544 8.46
Wasatch Advisors LP 3627308 3.75
Bellevue Group AG 3066400 3.17
Avoro Capital Advisors LLC 2255555 2.33
State Street Corporation 2220850 2.29
JP Morgan Chase & Company 2072615 2.14
Geode Capital Management, LLC 2001791 2.07
Deep Track Capital, LP 2000000 2.07

ETFShare, %Profitability for 1 year, %Dividends, %
PSYK ETF 6.54 0
Future Tech ETF 0.79497 426.34 0.8416
Principal Healthcare Innovators ETF 0.79497 618.5 0.8416
iShares Morningstar Small-Cap Growth ETF 0.32477 596.94 0.72598
Fidelity Growth Opportunities ETF 0.24923 -1.24 0.48881
iShares Morningstar Small-Cap ETF 0.16384 391.25 1.60498
1.47338.630.75



Head Job title Payment Year of birth
Mr. Michael I. Halstead J.D. President 983.65k 1973 (52 years)
Dr. Suresh K. Durgam M.D. Executive VP & Chief Medical Officer 961.84k 1969 (56 years)
Mr. Mark Neumann EVP & Chief Commercial Officer 998.36k 1963 (62 years)
Mr. Juan Fernando Sanchez Vice President of Corporate Communications & Investor Relations 296.75k 1971 (54 years)
Ms. Karen Patruno Sheehy Esq. Senior VP & Chief Compliance Officer N/A 1962 (63 years)
Dr. Michael Olchaskey Senior VP & Head of Regulatory Affairs N/A
Mr. John A. Bardi Senior VP of Market Access, Policy & Government Affairs N/A
Dr. Robert E. Davis Ph.D. Senior VP & Chief Scientific Officer 646.12k 1951 (74 years)
Dr. Sharon Mates Ph.D. Co-Founder, Chairman & CEO 2.23M 1953 (72 years)
John P. Condon Senior Vice President, General Counsel & Secretary

Address: United States, New York, 430 East 29th Street - open in Google maps, open in Yandex maps
Website: https://www.intracellulartherapies.com